English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  51804702    線上人數 :  1064
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"liu y n"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 76-85 / 128 (共13頁)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2020-05-26T09:26:59Z Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations Chen Y.-F;Hsieh M.-S;Wu S.-G;Chang Y.-L;Shih J.-Y;Liu Y.-N;Tsai M.-F;Tsai T.-H;Yu C.-J;Chih-Hsin Yang;Yang P.-C.; Chen Y.-F; Hsieh M.-S; Wu S.-G; Chang Y.-L; Shih J.-Y; Liu Y.-N; Tsai M.-F; Tsai T.-H; Yu C.-J; CHIH-HSIN YANG; Yang P.-C.
臺大學術典藏 2020-05-26T09:26:56Z IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer Shih J.-Y.;Chih-Hsin Yang;Yu S.-L;Chen H.-Y;Tsai T.-H;Wu S.-G;Tsai M.-F;Chang T.-H;Liu Y.-N; Liu Y.-N; Chang T.-H; Tsai M.-F; Wu S.-G; Tsai T.-H; Chen H.-Y; Yu S.-L; CHIH-HSIN YANG; Shih J.-Y.
臺大學術典藏 2020-05-26T09:26:48Z The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients Shih J.-Y.;Wen Y.-F;Chih-Hsin Yang;Yang P.-C;Yu C.-J;Chang Y.-L;Tsai M.-F;Liu Y.-N;Wu S-G; Wu S-G; Liu Y.-N; Tsai M.-F; Chang Y.-L; Yu C.-J; Yang P.-C; CHIH-HSIN YANG; Wen Y.-F; Shih J.-Y.
臺大學術典藏 2020-05-26T09:26:37Z Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non?�Small-cell Lung Cancer Shih J.-Y.;Chih-Hsin Yang;Wu S.-G;Liu Y.-N;Lin Y.-T; Lin Y.-T; Liu Y.-N; Wu S.-G; CHIH-HSIN YANG; Shih J.-Y.
臺大學術典藏 2020-05-26T09:26:26Z Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion Shih J.-Y.;Chih-Hsin Yang;Yu C.-J;Liu Y.-N;Wu S.-G; Wu S.-G; Liu Y.-N; Yu C.-J; CHIH-HSIN YANG; Shih J.-Y.
臺大學術典藏 2020-05-25T07:35:03Z Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib Yu C.-J.; Yang J.C.-H; Shih J.-Y; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Liu Y.-N; Su K.-Y; Chang Y.-L; Wu C.-T; Liao B.-C; Hsu C.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin
臺大學術典藏 2020-05-25T01:32:59Z Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer YEN-TING LIN; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; Shih J.-Y.
臺大學術典藏 2020-05-25T01:32:58Z Validation of immunohistochemistry for the detection of BRAF V600E-mutated lung adenocarcinomas Gow C.-H.; Hsieh M.-S.; YEN-TING LIN; Liu Y.-N.; Shih J.-Y.
臺大學術典藏 2020-05-25T01:32:56Z Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer Shih J.-Y.;Yu C.-J.;Liu Y.-N.;Wu S.-G.;Tsai T.-H.;YEN-TING LIN; YEN-TING LIN; Tsai T.-H.; Wu S.-G.; Liu Y.-N.; Yu C.-J.; Shih J.-Y.
臺大學術典藏 2020-05-20T05:11:43Z Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non�VSmall-cell Lung Cancer Shih J.-Y.;Yang J.C.-H.;Wu S.-G.;Liu Y.-N.;YEN-TING LIN; YEN-TING LIN; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; Shih J.-Y.

顯示項目 76-85 / 128 (共13頁)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
每頁顯示[10|25|50]項目